A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06650808 In Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs PF 6650808 (Primary)
- Indications Breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 24 Jul 2017 Planned End Date changed from 30 Jun 2017 to 1 Jul 2017.
- 24 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 1 Jul 2017.
- 10 Jun 2017 Biomarkers information updated